{"name":"Eisai Inc.","slug":"eisai-inc","ticker":"","exchange":"","domain":"eisai.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2753000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Lenvima","genericName":"LENVATINIB","slug":"lenvatinib","revenue":1053000000,"yoyGrowth":0,"percentOfTotal":38.2},{"name":"Aricept","genericName":"DONEPEZIL","slug":"donepezil","revenue":800000000,"yoyGrowth":0,"percentOfTotal":29.1},{"name":"Leqembi","genericName":"LECANEMAB","slug":"lecanemab","revenue":500000000,"yoyGrowth":0,"percentOfTotal":18.2},{"name":"Halaven","genericName":"ERIBULIN","slug":"eribulin","revenue":400000000,"yoyGrowth":0,"percentOfTotal":14.5}],"timeline":[{"date":"1990-01-01","label":"Hexalen first approved","drug":"Hexalen","drugSlug":"altretamine","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Aricept first approved","drug":"Aricept","drugSlug":"donepezil","type":"approval","sentiment":"positive"},{"date":"1999-01-01","label":"Ontak first approved","drug":"Ontak","drugSlug":"denileukin-diftitox","type":"approval","sentiment":"positive"},{"date":"1999-01-01","label":"Ontak first approved","drug":"Ontak","drugSlug":"e7777","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Banzel first approved","drug":"Banzel","drugSlug":"rufinamide","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Halaven first approved","drug":"Halaven","drugSlug":"eribulin","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Belviq first approved","drug":"Belviq","drugSlug":"lorcaserin","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Lenvima first approved","drug":"Lenvima","drugSlug":"lenvatinib","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Dayvigo first approved","drug":"Dayvigo","drugSlug":"lemborexant","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Leqembi first approved","drug":"Leqembi","drugSlug":"lecanemab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-31","label":"Lenvima PHASE3 readout","drug":"Lenvima","drugSlug":"lenvatinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-06-30","label":"Leqembi PHASE3 readout","drug":"Leqembi","drugSlug":"lecanemab","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":1453000000,"percentOfTotal":52.8,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"Lenvima","genericName":"LENVATINIB","slug":"lenvatinib","indication":"Endometrial carcinoma progressing after chemotherapy","status":"marketed","revenue":1053000000},{"name":"Halaven","genericName":"ERIBULIN","slug":"eribulin","indication":"Liposarcoma","status":"marketed","revenue":400000000},{"name":"Hexalen","genericName":"ALTRETAMINE","slug":"altretamine","indication":"Malignant tumor of ovary","status":"marketed"},{"name":"E7337","genericName":"E7337","slug":"e7337","indication":"FGFR-altered solid tumors (in development)","status":"phase_2"},{"name":"Cytarabine or Supportive Care","genericName":"Cytarabine or Supportive Care","slug":"cytarabine-or-supportive-care","indication":"Acute myeloid leukemia (AML)","status":"phase_3"},{"name":"Dacogen (decitabine) only","genericName":"Dacogen (decitabine) only","slug":"dacogen-decitabine-only","indication":"Myelodysplastic syndromes (MDS), including previously treated and untreated patients","status":"phase_3"},{"name":"E7389 (Eribulin Mesylate)","genericName":"E7389 (Eribulin Mesylate)","slug":"e7389-eribulin-mesylate","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"Ontak","genericName":"DENILEUKIN DIFTITOX","slug":"denileukin-diftitox","indication":"Primary cutaneous T-cell lymphoma","status":"marketed"},{"name":"Ontak","genericName":"E7777","slug":"e7777","indication":"Primary cutaneous T-cell lymphoma","status":"marketed"},{"name":"ZOL","genericName":"ZOL","slug":"zol","indication":"Multiple myeloma with bone lesions","status":"marketed"},{"name":"bexarotene with carboplatin and paclitaxel","genericName":"bexarotene with carboplatin and paclitaxel","slug":"bexarotene-with-carboplatin-and-paclitaxel","indication":"Advanced or metastatic non-small cell lung cancer (Phase 3)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":1300000000,"percentOfTotal":47.2,"drugCount":22,"colorKey":"immunology","drugs":[{"name":"Aricept","genericName":"DONEPEZIL","slug":"donepezil","indication":"Alzheimer's disease","status":"marketed","revenue":800000000},{"name":"Leqembi","genericName":"LECANEMAB","slug":"lecanemab","indication":"Alzheimer's disease","status":"marketed","revenue":500000000},{"name":"Midazolam HCI","genericName":"Midazolam HCI","slug":"midazolam-hci","indication":"Preoperative sedation and anxiolysis","status":"phase_3"},{"name":"Banzel","genericName":"RUFINAMIDE","slug":"rufinamide","indication":"Seizures associated with Lennox-Gastaut Syndrome","status":"marketed"},{"name":"E2007 (perampanel)","genericName":"E2007 (perampanel)","slug":"e2007-perampanel","indication":"Partial-onset seizures (adjunctive therapy)","status":"phase_3"},{"name":"E3810","genericName":"E3810","slug":"e3810","indication":"Schizophrenia","status":"phase_3"},{"name":"Replacement with Zonisamide","genericName":"Replacement with Zonisamide","slug":"replacement-with-zonisamide","indication":"Partial seizures (adjunctive therapy)","status":"marketed"},{"name":"zonisamide high dose group","genericName":"zonisamide high dose group","slug":"zonisamide-high-dose-group","indication":"Epilepsy (adjunctive therapy for partial seizures)","status":"marketed"},{"name":"APD356","genericName":"APD356","slug":"apd356","indication":"Multiple sclerosis","status":"phase_2"},{"name":"Adjunctive Zonisamide","genericName":"Adjunctive Zonisamide","slug":"adjunctive-zonisamide","indication":"Adjunctive therapy for partial seizures in epilepsy","status":"marketed"},{"name":"Aricept","genericName":"Aricept","slug":"aricept","indication":"Alzheimer's disease","status":"marketed"},{"name":"Aricept (donepezil IR 10 mg)","genericName":"Aricept (donepezil IR 10 mg)","slug":"aricept-donepezil-ir-10-mg","indication":"Mild to moderate Alzheimer's disease","status":"phase_3"},{"name":"Aricept (donepezil SR 23 mg)","genericName":"Aricept (donepezil SR 23 mg)","slug":"aricept-donepezil-sr-23-mg","indication":"Mild to moderate Alzheimer's disease","status":"phase_3"},{"name":"BOTULINUM TOXIN TYPE B","genericName":"BOTULINUM TOXIN TYPE B","slug":"botulinum-toxin-type-b","indication":"Cervical dystonia","status":"marketed"},{"name":"E2020-Donepezil hydrochloride","genericName":"E2020-Donepezil hydrochloride","slug":"e2020-donepezil-hydrochloride","indication":"Moderate to severe dementia of the Alzheimer's type","status":"phase_2"},{"name":"Eslicarbazepine Acetate tablets","genericName":"Eslicarbazepine Acetate tablets","slug":"eslicarbazepine-acetate-tablets","indication":"Partial-onset seizures","status":"phase_2"},{"name":"Fycompa","genericName":"Fycompa","slug":"fycompa","indication":"Idiopathic generalized epilepsy","status":"marketed"},{"name":"LEQEMBI","genericName":"LECANEMAB-IRMB","slug":"lecanemab-irmb","indication":"Alzheimer's disease","status":"marketed"},{"name":"Lecanemab IV","genericName":"Lecanemab IV","slug":"lecanemab-iv","indication":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage with confirmed amyloid pathology)","status":"phase_3"},{"name":"Lecanemab SC","genericName":"Lecanemab SC","slug":"lecanemab-sc","indication":"Mild cognitive impairment or mild dementia stage of Alzheimer's disease","status":"phase_3"},{"name":"Mecobalamin IM injection","genericName":"Mecobalamin IM injection","slug":"mecobalamin-im-injection","indication":"Vitamin B12 deficiency with neurological manifestations","status":"marketed"},{"name":"zonisamide low dose group","genericName":"zonisamide low dose group","slug":"zonisamide-low-dose-group","indication":"Epilepsy (adjunctive or monotherapy for partial seizures)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":41,"colorKey":"neuroscience","drugs":[{"name":"Eribulin-LF","genericName":"Eribulin-LF","slug":"eribulin-lf","indication":"Other","status":"phase_1"},{"name":"Experimental 1","genericName":"Experimental 1","slug":"experimental-1","indication":"Other","status":"marketed"},{"name":"Dayvigo","genericName":"LEMBOREXANT","slug":"lemborexant","indication":"Insomnia","status":"marketed"},{"name":"Drug: E5501","genericName":"Drug: E5501","slug":"drug-e5501","indication":"Other","status":"phase_1"},{"name":"E0671","genericName":"E0671","slug":"e0671","indication":"Other","status":"marketed"},{"name":"E2020","genericName":"E2020","slug":"e2020","indication":"Other","status":"marketed"},{"name":"E2022- New Formula Tape","genericName":"E2022- New Formula Tape","slug":"e2022-new-formula-tape","indication":"Other","status":"phase_1"},{"name":"E2027","genericName":"E2027","slug":"e2027","indication":"Other","status":"phase_2"},{"name":"E5555","genericName":"E5555","slug":"e5555","indication":"Other","status":"phase_2"},{"name":"E7449 plus carboplatin and paclitaxel","genericName":"E7449 plus carboplatin and paclitaxel","slug":"e7449-plus-carboplatin-and-paclitaxel","indication":"Other","status":"phase_1"},{"name":"E7820 plus cetuximab","genericName":"E7820 plus cetuximab","slug":"e7820-plus-cetuximab","indication":"Other","status":"phase_2"},{"name":"Eszopiclone 1 mg- Elderly","genericName":"Eszopiclone 1 mg- Elderly","slug":"eszopiclone-1-mg-elderly","indication":"Insomnia in elderly patients (sleep onset and sleep maintenance)","status":"phase_3"},{"name":"Eszopiclone 2 mg- Elderly","genericName":"Eszopiclone 2 mg- Elderly","slug":"eszopiclone-2-mg-elderly","indication":"Other","status":"phase_3"},{"name":"MENATETRANONE","genericName":"MENATETRANONE","slug":"menatetranone","indication":"Other","status":"marketed"},{"name":"Selbex","genericName":"Selbex","slug":"selbex","indication":"Other","status":"marketed"},{"name":"Suvorexant tablets, over-encapsulated","genericName":"Suvorexant tablets, over-encapsulated","slug":"suvorexant-tablets-over-encapsulated","indication":"Other","status":"phase_1"},{"name":"fospropofol disodium Subgroup 3 Approved Dose","genericName":"fospropofol disodium Subgroup 3 Approved Dose","slug":"fospropofol-disodium-subgroup-3-approved-dose","indication":"Other","status":"marketed"},{"name":"10-mg dose of E5501 cyclodextrin oral solution","genericName":"10-mg dose of E5501 cyclodextrin oral solution","slug":"10-mg-dose-of-e5501-cyclodextrin-oral-solution","indication":"Other","status":"phase_1"},{"name":"Amolimogene","genericName":"Amolimogene","slug":"amolimogene","indication":"Other","status":"phase_2"},{"name":"Any other approved Antiepileptic Drug","genericName":"Any other approved Antiepileptic Drug","slug":"any-other-approved-antiepileptic-drug","indication":"Other","status":"phase_3"},{"name":"E6201 0.01%","genericName":"E6201 0.01%","slug":"e6201-0-01","indication":"Other","status":"phase_2"},{"name":"Equfina","genericName":"Equfina","slug":"equfina","indication":"Other","status":"phase_2"},{"name":"Eszopiclone 2 mg- Non-elderly","genericName":"Eszopiclone 2 mg- Non-elderly","slug":"eszopiclone-2-mg-non-elderly","indication":"Insomnia (sleep initiation and maintenance) in non-elderly adults","status":"phase_3"},{"name":"Eszopiclone 3 mg- Non-elderly","genericName":"Eszopiclone 3 mg- Non-elderly","slug":"eszopiclone-3-mg-non-elderly","indication":"Insomnia (sleep initiation and maintenance) in non-elderly adults","status":"phase_3"},{"name":"Fospropofol disodium, propofol","genericName":"Fospropofol disodium, propofol","slug":"fospropofol-disodium-propofol","indication":"Other","status":"marketed"},{"name":"Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg","genericName":"Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg","slug":"group-a-e5501-5mg-then-20mg-then-40-mg-then-5mg","indication":"Other","status":"phase_1"},{"name":"HOPE","genericName":"HOPE","slug":"hope","indication":"Other","status":"marketed"},{"name":"Iomeprole","genericName":"Iomeprole","slug":"iomeprole","indication":"Other","status":"phase_2"},{"name":"Lorcaserin manufactured at Zofingen","genericName":"Lorcaserin manufactured at Zofingen","slug":"lorcaserin-manufactured-at-zofingen","indication":"Other","status":"phase_1"},{"name":"Lusedra","genericName":"Lusedra","slug":"lusedra","indication":"Sedation as Adjunct to Anesthesia","status":"phase_1"},{"name":"Mecobalamin IV Injection","genericName":"Mecobalamin IV Injection","slug":"mecobalamin-iv-injection","indication":"Other","status":"marketed"},{"name":"Mecobalamin IV or IM injection","genericName":"Mecobalamin IV or IM injection","slug":"mecobalamin-iv-or-im-injection","indication":"Other","status":"marketed"},{"name":"Pariet","genericName":"Pariet","slug":"pariet","indication":"Other","status":"marketed"},{"name":"Plasma Sampling","genericName":"Plasma Sampling","slug":"plasma-sampling","indication":"Other","status":"phase_1"},{"name":"Remitoro","genericName":"Remitoro","slug":"remitoro","indication":"Other","status":"phase_2"},{"name":"Safinamide Mesilate","genericName":"Safinamide Mesilate","slug":"safinamide-mesilate","indication":"Other","status":"marketed"},{"name":"Tasurgratinib","genericName":"Tasurgratinib","slug":"tasurgratinib","indication":"Other","status":"phase_1"},{"name":"Valsartin","genericName":"Valsartin","slug":"valsartin","indication":"Other","status":"marketed"},{"name":"fospropofol disodium Subgroup 2 Lower Dose","genericName":"fospropofol disodium Subgroup 2 Lower Dose","slug":"fospropofol-disodium-subgroup-2-lower-dose","indication":"Other","status":"marketed"},{"name":"lysozyme 90 mg","genericName":"lysozyme 90 mg","slug":"lysozyme-90-mg","indication":"Other","status":"marketed"},{"name":"palonesetron","genericName":"palonesetron","slug":"palonesetron","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"E7090","genericName":"E7090","slug":"e7090","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Belviq","genericName":"LORCASERIN","slug":"lorcaserin","indication":"Obesity","status":"marketed"},{"name":"lorcaserin + phentermine-HCl","genericName":"lorcaserin + phentermine-HCl","slug":"lorcaserin-phentermine-hcl","indication":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Eperisone hydrochloride and Diclofenac sodium","genericName":"Eperisone hydrochloride and Diclofenac sodium","slug":"eperisone-hydrochloride-and-diclofenac-sodium","indication":"Acute musculoskeletal pain and muscle spasticity","status":"phase_3"},{"name":"Eperisone hydrochloride","genericName":"Eperisone hydrochloride","slug":"eperisone-hydrochloride","indication":"Muscle tension and spasticity associated with musculoskeletal disorders","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Avatrombopag tablets","genericName":"Avatrombopag tablets","slug":"avatrombopag-tablets","indication":"Thrombocytopenia","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Lysozyme hydrochloride","genericName":"Lysozyme hydrochloride","slug":"lysozyme-hydrochloride","indication":"Bacterial infections (topical/local use)","status":"marketed"}]}],"pipeline":[{"name":"Lenvima","genericName":"LENVATINIB","slug":"lenvatinib","phase":"marketed","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells.","indications":["Endometrial carcinoma progressing after chemotherapy","Follicular thyroid carcinoma","Hurthle cell carcinoma of thyroid","Liver cell carcinoma","Papillary thyroid carcinoma"],"catalyst":""},{"name":"Aricept","genericName":"DONEPEZIL","slug":"donepezil","phase":"marketed","mechanism":"Aricept works by blocking the enzyme that breaks down a key neurotransmitter in the brain, acetylcholine.","indications":["Alzheimer's disease","Moderate to Severe Alzheimer's Type Dementia"],"catalyst":""},{"name":"Leqembi","genericName":"LECANEMAB","slug":"lecanemab","phase":"marketed","mechanism":"Leqembi works by binding to and removing amyloid beta A4 protein from the brain, which is thought to contribute to the progression of Alzheimer's disease.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Halaven","genericName":"ERIBULIN","slug":"eribulin","phase":"marketed","mechanism":"Halaven works by binding to tubulin beta, disrupting microtubule dynamics and leading to cell death.","indications":["Liposarcoma","Metastatic Breast Carcinoma"],"catalyst":""},{"name":"E7090","genericName":"E7090","slug":"e7090","phase":"phase_2","mechanism":"E7090 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Eribulin-LF","genericName":"Eribulin-LF","slug":"eribulin-lf","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Experimental 1","genericName":"Experimental 1","slug":"experimental-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hexalen","genericName":"ALTRETAMINE","slug":"altretamine","phase":"marketed","mechanism":"Cytochrome P450 1A2","indications":["Malignant tumor of ovary"],"catalyst":""},{"name":"Midazolam HCI","genericName":"Midazolam HCI","slug":"midazolam-hci","phase":"phase_3","mechanism":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation, anxiolysis, and muscle relaxation.","indications":["Preoperative sedation and anxiolysis","Induction of general anesthesia","Acute seizure management","Procedural sedation"],"catalyst":""},{"name":"Banzel","genericName":"RUFINAMIDE","slug":"rufinamide","phase":"marketed","mechanism":"Banzel works by stabilizing inactivated sodium channels in the brain, reducing the frequency of seizures.","indications":["Seizures associated with Lennox-Gastaut Syndrome"],"catalyst":""},{"name":"Belviq","genericName":"LORCASERIN","slug":"lorcaserin","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 2C","indications":["Obesity"],"catalyst":""},{"name":"Dayvigo","genericName":"LEMBOREXANT","slug":"lemborexant","phase":"marketed","mechanism":"Dayvigo blocks the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles.","indications":["Insomnia"],"catalyst":""},{"name":"Drug: E5501","genericName":"Drug: E5501","slug":"drug-e5501","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E0671","genericName":"E0671","slug":"e0671","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E2007 (perampanel)","genericName":"E2007 (perampanel)","slug":"e2007-perampanel","phase":"phase_3","mechanism":"Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain.","indications":["Partial-onset seizures (adjunctive therapy)","Generalized tonic-clonic seizures (adjunctive therapy)"],"catalyst":""},{"name":"E2020","genericName":"E2020","slug":"e2020","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E2022- New Formula Tape","genericName":"E2022- New Formula Tape","slug":"e2022-new-formula-tape","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E2027","genericName":"E2027","slug":"e2027","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E3810","genericName":"E3810","slug":"e3810","phase":"phase_3","mechanism":"E3810 is a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular cyclic nucleotide signaling in the brain.","indications":["Schizophrenia","Parkinson's disease psychosis"],"catalyst":""},{"name":"E5555","genericName":"E5555","slug":"e5555","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E7337","genericName":"E7337","slug":"e7337","phase":"phase_2","mechanism":"E7337 is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) signaling.","indications":["FGFR-altered solid tumors (in development)"],"catalyst":""},{"name":"E7449 plus carboplatin and paclitaxel","genericName":"E7449 plus carboplatin and paclitaxel","slug":"e7449-plus-carboplatin-and-paclitaxel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E7820 plus cetuximab","genericName":"E7820 plus cetuximab","slug":"e7820-plus-cetuximab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eperisone hydrochloride and Diclofenac sodium","genericName":"Eperisone hydrochloride and Diclofenac sodium","slug":"eperisone-hydrochloride-and-diclofenac-sodium","phase":"phase_3","mechanism":"This combination product uses eperisone as a muscle relaxant and diclofenac as an NSAID to reduce muscle tension and inflammation-related pain.","indications":["Acute musculoskeletal pain and muscle spasticity","Pain associated with muscle tension and inflammation"],"catalyst":""},{"name":"Eszopiclone 1 mg- Elderly","genericName":"Eszopiclone 1 mg- Elderly","slug":"eszopiclone-1-mg-elderly","phase":"phase_3","mechanism":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","indications":["Insomnia in elderly patients (sleep onset and sleep maintenance)"],"catalyst":""},{"name":"Eszopiclone 2 mg- Elderly","genericName":"Eszopiclone 2 mg- Elderly","slug":"eszopiclone-2-mg-elderly","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MENATETRANONE","genericName":"MENATETRANONE","slug":"menatetranone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Replacement with Zonisamide","genericName":"Replacement with Zonisamide","slug":"replacement-with-zonisamide","phase":"marketed","mechanism":"Zonisamide is an anticonvulsant that blocks sodium and calcium channels in neurons, reducing abnormal electrical activity in the brain.","indications":["Partial seizures (adjunctive therapy)","Generalized tonic-clonic seizures (adjunctive therapy)","Lennox-Gastaut syndrome (adjunctive therapy)"],"catalyst":""},{"name":"Selbex","genericName":"Selbex","slug":"selbex","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Suvorexant tablets, over-encapsulated","genericName":"Suvorexant tablets, over-encapsulated","slug":"suvorexant-tablets-over-encapsulated","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"fospropofol disodium Subgroup 3 Approved Dose","genericName":"fospropofol disodium Subgroup 3 Approved Dose","slug":"fospropofol-disodium-subgroup-3-approved-dose","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"zonisamide high dose group","genericName":"zonisamide high dose group","slug":"zonisamide-high-dose-group","phase":"marketed","mechanism":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition.","indications":["Epilepsy (adjunctive therapy for partial seizures)","Generalized tonic-clonic seizures"],"catalyst":""},{"name":"10-mg dose of E5501 cyclodextrin oral solution","genericName":"10-mg dose of E5501 cyclodextrin oral solution","slug":"10-mg-dose-of-e5501-cyclodextrin-oral-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APD356","genericName":"APD356","slug":"apd356","phase":"phase_2","mechanism":"APD356 is a selective agonist of the cannabinoid receptor type 2 (CB2).","indications":["Multiple sclerosis"],"catalyst":""},{"name":"Adjunctive Zonisamide","genericName":"Adjunctive Zonisamide","slug":"adjunctive-zonisamide","phase":"marketed","mechanism":"Zonisamide is an anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade and carbonic anhydrase inhibition.","indications":["Adjunctive therapy for partial seizures in epilepsy","Adjunctive therapy for generalized tonic-clonic seizures"],"catalyst":""},{"name":"Amolimogene","genericName":"Amolimogene","slug":"amolimogene","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Any other approved Antiepileptic Drug","genericName":"Any other approved Antiepileptic Drug","slug":"any-other-approved-antiepileptic-drug","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aricept","genericName":"Aricept","slug":"aricept","phase":"marketed","mechanism":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","indications":["Alzheimer's disease","Moderate to Severe Alzheimer's Type Dementia"],"catalyst":""},{"name":"Aricept (donepezil IR 10 mg)","genericName":"Aricept (donepezil IR 10 mg)","slug":"aricept-donepezil-ir-10-mg","phase":"phase_3","mechanism":"Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease.","indications":["Mild to moderate Alzheimer's disease","Cognitive decline associated with Alzheimer's disease"],"catalyst":""},{"name":"Aricept (donepezil SR 23 mg)","genericName":"Aricept (donepezil SR 23 mg)","slug":"aricept-donepezil-sr-23-mg","phase":"phase_3","mechanism":"Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down.","indications":["Mild to moderate Alzheimer's disease","Moderate to severe Alzheimer's disease"],"catalyst":""},{"name":"Avatrombopag tablets","genericName":"Avatrombopag tablets","slug":"avatrombopag-tablets","phase":"phase_2","mechanism":"Thrombopoietin receptor agonist","indications":["Thrombocytopenia"],"catalyst":""},{"name":"BOTULINUM TOXIN TYPE B","genericName":"BOTULINUM TOXIN TYPE B","slug":"botulinum-toxin-type-b","phase":"marketed","mechanism":"Botulinum toxin type B blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Strabismus","Hyperhidrosis","Migraine prophylaxis"],"catalyst":""},{"name":"Cytarabine or Supportive Care","genericName":"Cytarabine or Supportive Care","slug":"cytarabine-or-supportive-care","phase":"phase_3","mechanism":"Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, thereby killing rapidly dividing cells.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)","Chronic myeloid leukemia (CML) in blast phase","Lymphoma"],"catalyst":""},{"name":"Dacogen (decitabine) only","genericName":"Dacogen (decitabine) only","slug":"dacogen-decitabine-only","phase":"phase_3","mechanism":"Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells.","indications":["Myelodysplastic syndromes (MDS), including previously treated and untreated patients","Acute myeloid leukemia (AML) in elderly patients ineligible for intensive chemotherapy"],"catalyst":""},{"name":"E2020-Donepezil hydrochloride","genericName":"E2020-Donepezil hydrochloride","slug":"e2020-donepezil-hydrochloride","phase":"phase_2","mechanism":"Donepezil hydrochloride is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain, which helps to improve cognitive function in patients with Alzheimer's disease.","indications":["Moderate to severe dementia of the Alzheimer's type"],"catalyst":""},{"name":"E6201 0.01%","genericName":"E6201 0.01%","slug":"e6201-0-01","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"E7389 (Eribulin Mesylate)","genericName":"E7389 (Eribulin Mesylate)","slug":"e7389-eribulin-mesylate","phase":"phase_3","mechanism":"Eribulin is a microtubule dynamics inhibitor that suppresses microtubule growth and induces apoptosis in cancer cells.","indications":["Metastatic breast cancer","Liposarcoma","Other solid tumors (in clinical development)"],"catalyst":""},{"name":"Eperisone hydrochloride","genericName":"Eperisone hydrochloride","slug":"eperisone-hydrochloride","phase":"phase_3","mechanism":"Eperisone hydrochloride is a muscle relaxant that reduces muscle tension by inhibiting monoamine oxidase and enhancing noradrenergic and serotonergic neurotransmission in the central nervous system.","indications":["Muscle tension and spasticity associated with musculoskeletal disorders","Cervical spondylosis with muscle stiffness","Lower back pain with muscle tension"],"catalyst":""},{"name":"Equfina","genericName":"Equfina","slug":"equfina","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eslicarbazepine Acetate tablets","genericName":"Eslicarbazepine Acetate tablets","slug":"eslicarbazepine-acetate-tablets","phase":"phase_2","mechanism":"Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes neuronal membranes and suppresses post-tetanic potentiation.","indications":["Partial-onset seizures"],"catalyst":""},{"name":"Eszopiclone 2 mg- Non-elderly","genericName":"Eszopiclone 2 mg- Non-elderly","slug":"eszopiclone-2-mg-non-elderly","phase":"phase_3","mechanism":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.","indications":["Insomnia (sleep initiation and maintenance) in non-elderly adults"],"catalyst":""},{"name":"Eszopiclone 3 mg- Non-elderly","genericName":"Eszopiclone 3 mg- Non-elderly","slug":"eszopiclone-3-mg-non-elderly","phase":"phase_3","mechanism":"Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to enhance inhibitory neurotransmission and promote sleep.","indications":["Insomnia (sleep initiation and maintenance) in non-elderly adults"],"catalyst":""},{"name":"Fospropofol disodium, propofol","genericName":"Fospropofol disodium, propofol","slug":"fospropofol-disodium-propofol","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fycompa","genericName":"Fycompa","slug":"fycompa","phase":"marketed","mechanism":"Glutamate receptor ionotropic AMPA","indications":["Idiopathic generalized epilepsy","Partial seizure","Secondarily generalized seizures"],"catalyst":""},{"name":"Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg","genericName":"Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg","slug":"group-a-e5501-5mg-then-20mg-then-40-mg-then-5mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HOPE","genericName":"HOPE","slug":"hope","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iomeprole","genericName":"Iomeprole","slug":"iomeprole","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LEQEMBI","genericName":"LECANEMAB-IRMB","slug":"lecanemab-irmb","phase":"marketed","mechanism":"Amyloid beta A4 protein","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Lecanemab IV","genericName":"Lecanemab IV","slug":"lecanemab-iv","phase":"phase_3","mechanism":"Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.","indications":["Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage with confirmed amyloid pathology)"],"catalyst":""},{"name":"Lecanemab SC","genericName":"Lecanemab SC","slug":"lecanemab-sc","phase":"phase_3","mechanism":"Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.","indications":["Mild cognitive impairment or mild dementia stage of Alzheimer's disease"],"catalyst":""},{"name":"Lorcaserin manufactured at Zofingen","genericName":"Lorcaserin manufactured at Zofingen","slug":"lorcaserin-manufactured-at-zofingen","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lusedra","genericName":"Lusedra","slug":"lusedra","phase":"phase_1","mechanism":"GABA-A receptor","indications":["Sedation as Adjunct to Anesthesia"],"catalyst":""},{"name":"Lysozyme hydrochloride","genericName":"Lysozyme hydrochloride","slug":"lysozyme-hydrochloride","phase":"marketed","mechanism":"Lysozyme hydrochloride is an antimicrobial enzyme that breaks down bacterial cell walls by cleaving peptidoglycan, thereby killing bacteria and reducing infection.","indications":["Bacterial infections (topical/local use)","Dry eye syndrome (as a component of tear substitutes)"],"catalyst":""},{"name":"Mecobalamin IM injection","genericName":"Mecobalamin IM injection","slug":"mecobalamin-im-injection","phase":"marketed","mechanism":"Mecobalamin is an active form of vitamin B12 that replenishes cellular cobalamin stores and restores normal methylation and energy metabolism.","indications":["Vitamin B12 deficiency with neurological manifestations","Peripheral neuropathy associated with B12 deficiency","Subacute combined degeneration","Pernicious anemia with neurological complications"],"catalyst":""},{"name":"Mecobalamin IV Injection","genericName":"Mecobalamin IV Injection","slug":"mecobalamin-iv-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mecobalamin IV or IM injection","genericName":"Mecobalamin IV or IM injection","slug":"mecobalamin-iv-or-im-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ontak","genericName":"DENILEUKIN DIFTITOX","slug":"denileukin-diftitox","phase":"marketed","mechanism":"Ontak works by binding to the interleukin-2 receptor on cancer cells, triggering a toxic response that kills the cells.","indications":["Primary cutaneous T-cell lymphoma","Refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"Ontak","genericName":"E7777","slug":"e7777","phase":"marketed","mechanism":"Interleukin-2 receptor","indications":["Primary cutaneous T-cell lymphoma","Refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"Pariet","genericName":"Pariet","slug":"pariet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Plasma Sampling","genericName":"Plasma Sampling","slug":"plasma-sampling","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Remitoro","genericName":"Remitoro","slug":"remitoro","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Safinamide Mesilate","genericName":"Safinamide Mesilate","slug":"safinamide-mesilate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tasurgratinib","genericName":"Tasurgratinib","slug":"tasurgratinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Valsartin","genericName":"Valsartin","slug":"valsartin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZOL","genericName":"ZOL","slug":"zol","phase":"marketed","mechanism":"ZOL (zoledronic acid) is a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","indications":["Multiple myeloma with bone lesions","Metastatic bone disease from solid tumors","Osteoporosis","Paget's disease of bone","Hypercalcemia of malignancy"],"catalyst":""},{"name":"bexarotene with carboplatin and paclitaxel","genericName":"bexarotene with carboplatin and paclitaxel","slug":"bexarotene-with-carboplatin-and-paclitaxel","phase":"phase_3","mechanism":"This combination uses bexarotene (a retinoid X receptor agonist) to enhance immune response alongside carboplatin and paclitaxel chemotherapy agents that damage cancer cell DNA and disrupt microtubule function.","indications":["Advanced or metastatic non-small cell lung cancer (Phase 3)"],"catalyst":""},{"name":"fospropofol disodium Subgroup 2 Lower Dose","genericName":"fospropofol disodium Subgroup 2 Lower Dose","slug":"fospropofol-disodium-subgroup-2-lower-dose","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"lorcaserin + phentermine-HCl","genericName":"lorcaserin + phentermine-HCl","slug":"lorcaserin-phentermine-hcl","phase":"marketed","mechanism":"This combination uses lorcaserin (a 5-HT2C receptor agonist) to reduce appetite and phentermine (a sympathomimetic amine) to increase energy expenditure and suppress appetite for weight management.","indications":["Chronic weight management in adults with obesity or overweight with weight-related comorbidities"],"catalyst":""},{"name":"lysozyme 90 mg","genericName":"lysozyme 90 mg","slug":"lysozyme-90-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"palonesetron","genericName":"palonesetron","slug":"palonesetron","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"zonisamide low dose group","genericName":"zonisamide low dose group","slug":"zonisamide-low-dose-group","phase":"marketed","mechanism":"Zonisamide inhibits multiple ion channels and carbonic anhydrase to reduce neuronal excitability and seizure activity.","indications":["Epilepsy (adjunctive or monotherapy for partial seizures)","Generalized tonic-clonic seizures"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9SLTBJbDZQYnNIQVhkSTVrZjFQcEw1WGxzVFloQmRXTEp2aUJONUkzQWJ2WldPZUFSTWZXdFdpYkhNdl93a0JSZTBobmdDS0pLOEVTTk5XUFkwZmJPVGRnVDRuVGNyMGJTalJlaXU4VkpSS3M3VEQxSA?oc=5","date":"2026-02-06","type":"pipeline","source":"pharmaphorum","summary":"Leqembi starts to deliver for Eisai and Biogen - pharmaphorum","headline":"Leqembi starts to deliver for Eisai and Biogen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQR3l4MHN1T0pmUjl0TkJSc25UeDBYN0hvdXRPemZoWnFWUlF0d0NIaUhXS01IXzY5WVh2UW1xWEJBVVQwZ3ZKeV96T1NjbXhQYzJsdjFZSGY0eEVCeTNOZFk0NnlnS20yY2U3aU5lMWdnb1BlWi1SNGc5Y1AtM1hwNWVNTGIwRTVaUXNaaFc1TUxnQ0dMeWh3cndqT0Y4LTVqUkg3VkdCR3AtMDhxcWZPRTFXaWlRcEtMblBmd2RlNUtpaW94bExUQ0VidXhNdw?oc=5","date":"2026-02-06","type":"deal","source":"Contract Pharma","summary":"Eisai, Henlius Strike Japan Commercialization Deal for PD‑1 Antibody Serplulimab - Contract Pharma","headline":"Eisai, Henlius Strike Japan Commercialization Deal for PD‑1 Antibody Serplulimab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQcWo0Q0p4NjFUWTBEbFRJYVQ3WDFzLUJxcGt2b3N3MFBjWkdSVDdQcEwwM3BwTUROZGxUczdNNVBBTDRnRTdpUC0zVUZySFpwSUs4c3VMZzBLWlA2eWJhdWlGZDRiNzMwMFhxZFhxWmdPMjJVc3lZN3RkX2ZNRjBTSWE1cUFieVNlSWNnZmlkNHFBdDB2c09zQzcxYWZSNk1jeC1GdkRPVQ?oc=5","date":"2026-01-16","type":"deal","source":"The Pharma Letter","summary":"Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter","headline":"Eisai and Nuvation Bio ink licensing deal for taletrectinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNSXBvSjJ0ckFhWDFIZ2k2dENaVkowZGQ3enVNNHpITHNoamVKREEzSXgzSmRJSUEzOXA1S01sSmttMHlUUjNCczJ4TklrSHVoYmlwMm92QnRtT2drNHVBVEM2Z0pxbExKdFdJSnkwSV9IM1RmNm1KcU1sQkVveERDcUpsdTdiTFNGbWJub0FaQ2NiU1ZaNnNQR0ZXZzhNQUYzbjFuZFBLNG5vSko4eUd1TTNfSkxnQWkyZ1hIU2dnMDllQlZWalNMWHNvZ2RHOG9vSFhST09Wc3gwSEkyZjdROVRBcS1GTUk0VHp6U1U2Vlo5YU5qc2xNT0F2LS1HVC1pVTR3NFZsNE13eVJUUThVRGtjMXVTOWs?oc=5","date":"2026-01-07","type":"trial","source":"BioSpace","summary":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - BioSpace","headline":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPQ2dHS2pzZ2lxekJ2VW5uQlFPTHBDcWtIeWxkdk5sVHQ3cVZRNkRrUlV4SHdGd3l1SUlEN1B6UGR3N1JzYXFZRHk1ZVBjejNBUHZBMzlhUVFIVUdyWHJydkV6QUphbGZCYmhuYmpnYWxCaEVSQzNNenlfeVp0dEJ5WVp3ak5BbmxmREltdXdBSFNlQXRqM0dnR3dsS2JlNHgwd29oRjBhMzR5ZWx4cmVpbE9fbkFNdjQ?oc=5","date":"2026-01-04","type":"pipeline","source":"AD HOC NEWS","summary":"Eisai Co Ltd Is Quietly Exploding – Here’s Why Smart Money Won’t Shut Up About It - AD HOC NEWS","headline":"Eisai Co Ltd Is Quietly Exploding – Here’s Why Smart Money Won’t Shut Up About It","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxONEllRTZqTU5qalAtc3U2NUVmWWJDX284NXBOTEhWdTN2QzRYa2h5OUtzdTdrc0R4YlpVY3JBOTdEMklYQXRZb3VLM25OdU82TE5OdFh5TEFhOTljYmZHcnVkU1dTQzVxZDhxdmE1TW1YN1RFRGM5dGpMbXlzc240V0twcEZBeUFOdXFuaWRJaF8xRFVvUzRHV2tnMERLYlhQb1dLUFAxU1FNSWpqOVNSa2VZZk5kV2IwYUtoQi1DOF9iQlhkS0pWTm1KbFU5QVhtakE?oc=5","date":"2025-08-29","type":"regulatory","source":"Reuters","summary":"US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters","headline":"US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNR2V1Q0tsZ1BIWHFZX3phMjZMNGhVeUJaaWREdC0xcHd4VWhjTVFnUl9qVTY2dk1Ia2NZMmx1MVJTZGlFMW9MNGstQWR3TmdfUnVzM2ZaTWhPR1M5MVlza1l6SU90ejJZX3Znc29rRU5BVUdBQ0dDdGtUOXVFaUlBN3FhN2Q3SmQz?oc=5","date":"2025-08-12","type":"pipeline","source":"Yahoo Finance","summary":"United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK - Yahoo Finance","headline":"United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQaU5rTmxDQjVXMjF2eVU2cExJN0ZzNlhETWdUVFFLQ3gxYzM2aUxzaVNYWmd4empXUHJJU3V0cUtBcnVKSTRCNTdMd1hTa2JyaGwtQXdaUVZFTVB2WHFJT0tuaEl0ZTdvc2pVTW95Q3k2VHE1WXUzVmRSdHpLcUxyQWN2NkxaYks1MXdseERnUEVwQVJyVDhRbkNPbm5OMzVqUEo3NVFIRVU5bEdxcFpsZ0VTM0FPcmdDMXp2bFVuVDZfUjBjTEdtQ0ctQmJsc1U0SHc?oc=5","date":"2025-07-21","type":"pipeline","source":"ehealth.eletsonline.com","summary":"Eisai Pharmaceuticals to Launch GCC in Visakhapatnam, Accelerating Digital Healthcare Innovation - ehealth.eletsonline.com","headline":"Eisai Pharmaceuticals to Launch GCC in Visakhapatnam, Accelerating Digital Healthcare Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQUm9LSHFtYWdBSHhEb2pDNzc1b3Mtc2Z2RXZBQ1pQS29QcU0tRm9jakpxd25IR2dadUdwVVhjY3czLTFRdDZKbHl6LXlMM1p3M1dZeVp0Q1FGOGRkMGNNbVFpa0swcDBBSFBPZGxiRzEtZ0Zjd1QtM0RuWTRpQ1pxMzJ4R1FqR3RTWjRGRFJtdVNoTHJxbDdMSV81X29qdWs3N1B3Tm1IY3lYMF9oQUxkcU53SDdETnVJT1VCSjdn?oc=5","date":"2025-07-17","type":"pipeline","source":"Business Wire","summary":"Elix Provides AI Drug Discovery Platform “Elix Discovery™” to Eisai - Business Wire","headline":"Elix Provides AI Drug Discovery Platform “Elix Discovery™” to Eisai","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-10","type":"pipeline","source":"The Times of India","summary":"Eisai Pharma to establish GCC in Visakhapatnam - The Times of India","headline":"Eisai Pharma to establish GCC in Visakhapatnam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFAyM1R2ZENMTVJoUzcwRmhsWmdickMyZDhxUlNKVG9rcExwTlJaeHJ2b0pQSHVBNHpBMWFFVVlJYmZiblNIaTlSR0ZUZ2tjb1llSU5TT1lJZE1Odw?oc=5","date":"2021-02-19","type":"pipeline","source":"Eisai","summary":"Video Library | About Eisai - Eisai","headline":"Video Library | About Eisai","sentiment":"neutral"}],"patents":[],"drugCount":81,"phaseCounts":{"marketed":37,"phase_2":15,"phase_1":11,"phase_3":18},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}